5 Best Gene Editing Stocks To Buy

Page 1 of 5

In this article, we discuss 5 best gene editing stocks to buy. If you want to see more stocks in this selection, check out 10 Best Gene Editing Stocks To Buy

5. Graphite Bio, Inc. (NASDAQ:GRPH)

Number of Hedge Fund Holders: 20

Graphite Bio, Inc. (NASDAQ:GRPH) is a clinical-stage gene editing company based in San Francisco, California. It develops therapies for life-threatening diseases in the United States. Graphite Bio, Inc. (NASDAQ:GRPH) is one of the best gene editing stocks to invest in. As of June 30, the company reported that cash, cash equivalents, and investments in marketable securities came in at $328.3 million. Graphite Bio, Inc. (NASDAQ:GRPH) believes that this money can fund planned operations into the fourth quarter of 2024.

On September 15, Cantor Fitzgerald analyst Olivia Brayer initiated coverage of Graphite Bio, Inc. (NASDAQ:GRPH) with an Overweight rating and a $12 price target. The company’s primary program is still in early stages, but it is gaining visibility in the sickle cell disease space given its potentially unique and curative approach, the analyst told investors. 

According to Insider Monkey’s data, 20 hedge funds were bullish on Graphite Bio, Inc. (NASDAQ:GRPH) at the end of June 2022, up from 12 funds in the prior quarter. Samsara BioCapital is the leading position holder in the company, with 8.45 million shares worth $23.2 million. 

Page 1 of 5